Los puntos clave no están disponibles para este artículo en este momento.
Our findings support the use of the HFMSE as a key outcome measure in SMA clinical trials because the individual items and the detected changes have clear content validity and clinical meaningfulness for patients and their caregivers.
Pera et al. (Thu,) studied this question.